Senores Pharmaceuticals, via its US subsidiary, will acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA. The products have a US market opportunity of $38 million and $120 million. The deal will be funded through IPO proceeds, aligning with SPL’s plan to expand its US generics portfolio and strengthen its position in regulated markets.